Table 2.
Univariate analysis of prognostic factors for locoregional recurrence, distant metastasis, disease-free survival and overall survival.
| Characteristic | LRR | DM | DFS | OS | ||||
|---|---|---|---|---|---|---|---|---|
| Hazard ratio(95%CI) | P | Hazard ratio(95%CI) | P | Hazard ratio(95%CI) | P | Hazard ratio(95%CI) | P | |
| Treatment period (years) | ||||||||
| 2008–2013 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| 2014–2016 | 0.55 (0.29–1.05) | .066 | 0.63 (0.44–0.90) | .010 | 0.62 (0.44–0.88) | .006 | 0.62 (0.39–0.98) | .041 |
| Age (years) | ||||||||
| <40 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| ≥40 | 0.70 (0.40–1.22) | .213 | 0.60 (0.44–0.82) | .002 | 0.62 (0.46–0.85) | .002 | 0.77 (0.53–1.12) | .167 |
| Stage | ||||||||
| II–IIIA | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| IIIB–IIIC | 1.58 (0.99–2.53) | .055 | 1.99 (1.52–2.62) | <.001 | 1.98 (1.53–2.57) | <.001 | 2.26 (1.66–3.08) | <.001 |
| Lymphovascular invasion | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 1.54 (0.96–2.48) | .077 | 1.26 (0.95–1.67) | .110 | 1.24 (0.95–1.63) | .112 | 1.38 (1.01–1.90) | .045 |
| Histology grade | ||||||||
| I–II | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| III | 1.17 (0.69–1.98) | .562 | 1.01 (0.74–1.38) | .932 | 1.05 (0.78–1.41) | .738 | 1.33 (0.94–1.87) | .101 |
| Hormonal receptor | ||||||||
| Negative | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Positive | 0.57 (0.33–0.96) | .034 | 0.75 (0.54–1.04) | .080 | 0.72 (0.53–0.98) | .039 | 0.51 (0.36–0.72) | <.001 |
| Neoadjuvant chemotherapy | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 1.65 (1.01–2.71) | .047 | 1.41 (1.05–1.89) | .024 | 1.43 (1.08–1.90) | .014 | 1.59 (1.15–2.21) | .005 |
| Radiation fractionation | ||||||||
| HFRT | 1.00 | 1.00 | 1.00 | |||||
| CFRT | 0.80 (0.50–1.29) | .363 | 1.09 (0.83–1.43) | .531 | 1.07 (0.83–1.39) | .60 | 1.06 (0.78–1.44) | .713 |
| Hormonal therapy | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 0.46 (0.28–0.77) | .003 | 0.79 (0.51–0.94) | .019 | 0.66 (0.49–0.88) | .005 | 1.06 (0.99–1.14) | <.001 |
| HER2 and trastuzumab | .008 | .001 | .001 | .089 | ||||
| HER2− | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| HER2+ + T | 0.86 (0.42–1.77) | .681 | 0.72 (0.47–1.10) | .125 | 0.81 (0.54–1.19) | .277 | 0.90 (0.57–1.41) | .638 |
| HER2+ − T | 2.28 (1.31–3.95) | .003 | 1.67 (1.18–2.35) | .003 | 1.73 (1.25–2.40) | .001 | 1.52 (1.03–2.26) | .037 |
LRR, locoregional recurrence; DM, distant metastasis; DFS, disease-free survival; OS, overall survival; HFRT, hypofractionated radiation therapy; CFRT, conventional fractionated radiation therapy; HER2, human epidermal growth factor receptor 2; HER2−, HER2-negative; HER2+ + T, HER2-positive with trastuzumab; HER2+ − T, HER2-positive without trastuzumab.